Chinese General Practice ›› 2023, Vol. 26 ›› Issue (30): 3748-3752.DOI: 10.12114/j.issn.1007-9572.2023.0214
• Original Research • Previous Articles Next Articles
Received:
2023-02-12
Revised:
2023-05-10
Published:
2023-10-20
Online:
2023-05-29
Contact:
WEI Cuiying
通讯作者:
魏翠英
作者简介:
基金资助:
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.chinagp.net/EN/10.12114/j.issn.1007-9572.2023.0214
分组 | 例数 | 性别(男/女) | 年龄(岁) | BMI(kg/m2) | FBG〔M(P25,P75),mmol/L〕 | TC(mmol/L) | TG(mmol/L) | LDL-C(mmol/L) | HDL-C(mmol/L) | UA(mmol/L) | FINS(μU/mL) | HbA1c〔M(P25,P75),%〕 |
---|---|---|---|---|---|---|---|---|---|---|---|---|
对照组 | 62 | 41/21 | 59.3±12.2 | 24.6±3.6 | 6.4(5.3,9.7) | 4.25±1.42 | 1.82±1.51 | 2.68±1.28 | 1.13±0.38 | 369.73±110.53 | 4.74±2.66 | 6.9(5.9,8.9) |
轻度OSAS组 | 31 | 24/7 | 54.7±11.8 | 26.0±3.6 | 8.0(5.3,11.5) | 4.54±1.09 | 2.17±1.29 | 2.98±0.99 | 1.09±0.28 | 377.13±96.27 | 6.36±2.42a | 8.3(5.6,9.7) |
中重度OSAS组 | 26 | 20/6 | 56.3±9.0 | 29.0±3.8ab | 6.0(4.9,7.3) | 4.37±0.96 | 2.38±1.99 | 2.76±0.88 | 1.03±0.32 | 398.04±87.42 | 10.50±3.15ab | 6.4(5.5,8.3) |
检验统计量值 | 4.66d | 1.76 | 13.19 | 3.46c | 0.58 | 1.28 | 0.74 | 0.82 | 0.70 | 41.27 | 1.68c | |
P值 | 0.10 | 0.18 | <0.01 | 1.77 | 0.56 | 0.28 | 0.48 | 0.44 | 0.50 | <0.01 | 0.43 |
Table 1 Comparison of general data and biochemical indexes among the three groups
分组 | 例数 | 性别(男/女) | 年龄(岁) | BMI(kg/m2) | FBG〔M(P25,P75),mmol/L〕 | TC(mmol/L) | TG(mmol/L) | LDL-C(mmol/L) | HDL-C(mmol/L) | UA(mmol/L) | FINS(μU/mL) | HbA1c〔M(P25,P75),%〕 |
---|---|---|---|---|---|---|---|---|---|---|---|---|
对照组 | 62 | 41/21 | 59.3±12.2 | 24.6±3.6 | 6.4(5.3,9.7) | 4.25±1.42 | 1.82±1.51 | 2.68±1.28 | 1.13±0.38 | 369.73±110.53 | 4.74±2.66 | 6.9(5.9,8.9) |
轻度OSAS组 | 31 | 24/7 | 54.7±11.8 | 26.0±3.6 | 8.0(5.3,11.5) | 4.54±1.09 | 2.17±1.29 | 2.98±0.99 | 1.09±0.28 | 377.13±96.27 | 6.36±2.42a | 8.3(5.6,9.7) |
中重度OSAS组 | 26 | 20/6 | 56.3±9.0 | 29.0±3.8ab | 6.0(4.9,7.3) | 4.37±0.96 | 2.38±1.99 | 2.76±0.88 | 1.03±0.32 | 398.04±87.42 | 10.50±3.15ab | 6.4(5.5,8.3) |
检验统计量值 | 4.66d | 1.76 | 13.19 | 3.46c | 0.58 | 1.28 | 0.74 | 0.82 | 0.70 | 41.27 | 1.68c | |
P值 | 0.10 | 0.18 | <0.01 | 1.77 | 0.56 | 0.28 | 0.48 | 0.44 | 0.50 | <0.01 | 0.43 |
分组 | 例数 | Metrnl(ng/L) | NF-κB(ng/L) | IL-6(ng/L) | TNF-α(ng/L) | IL-10(ng/L) | IL-4(ng/L) | HOMA-IR |
---|---|---|---|---|---|---|---|---|
对照组 | 62 | 69.95±9.29 | 860.85±113.42 | 32.28±5.10 | 51.51±7.63 | 610.22±71.55 | 26.26±5.86 | 1.46±0.76 |
轻度OSAS组 | 31 | 56.59±6.65a | 1 003.52±106.53a | 36.91±5.07a | 58.11±8.37a | 558.15±97.96a | 26.26±6.90 | 2.12±0.49a |
中重度OSAS组 | 26 | 53.29±6.43ab | 1 020.72±133.85a | 39.23±6.36a | 66.09±9.48ab | 565.73±99.01a | 25.18±5.85 | 2.99±1.17ab |
F值 | 51.02 | 24.96 | 19.95 | 29.29 | 5.97 | 0.36 | 33.74 | |
P值 | <0.01 | <0.01 | <0.01 | <0.01 | <0.01 | 0.70 | <0.01 |
Table 2 Comparison of adipokine Metrnl,inflammatory factor and HOMA-IR among the three groups
分组 | 例数 | Metrnl(ng/L) | NF-κB(ng/L) | IL-6(ng/L) | TNF-α(ng/L) | IL-10(ng/L) | IL-4(ng/L) | HOMA-IR |
---|---|---|---|---|---|---|---|---|
对照组 | 62 | 69.95±9.29 | 860.85±113.42 | 32.28±5.10 | 51.51±7.63 | 610.22±71.55 | 26.26±5.86 | 1.46±0.76 |
轻度OSAS组 | 31 | 56.59±6.65a | 1 003.52±106.53a | 36.91±5.07a | 58.11±8.37a | 558.15±97.96a | 26.26±6.90 | 2.12±0.49a |
中重度OSAS组 | 26 | 53.29±6.43ab | 1 020.72±133.85a | 39.23±6.36a | 66.09±9.48ab | 565.73±99.01a | 25.18±5.85 | 2.99±1.17ab |
F值 | 51.02 | 24.96 | 19.95 | 29.29 | 5.97 | 0.36 | 33.74 | |
P值 | <0.01 | <0.01 | <0.01 | <0.01 | <0.01 | 0.70 | <0.01 |
指标 | 控制因素 | r值 | P值 |
---|---|---|---|
AHI | 炎症因子、BMI、HOMA-IR | -0.51 | <0.01 |
NF-κB | 年龄、BMI、HOMA-IR | -0.30 | 0.01 |
IL-6 | 年龄、BMI、HOMA-IR | -0.40 | <0.01 |
TNF-α | 年龄、BMI、HOMA-IR | -0.37 | <0.01 |
IL-10 | 年龄、BMI、HOMA-IR | 0.27 | <0.01 |
HOMA-IR | 炎症因子、BMI | -0.36 | <0.01 |
FBG | 炎症因子、BMI | -0.32 | <0.01 |
HbA1c | 炎症因子、BMI | -0.33 | <0.05 |
Table 3 Correlation analysis between Metrnl and other indicators
指标 | 控制因素 | r值 | P值 |
---|---|---|---|
AHI | 炎症因子、BMI、HOMA-IR | -0.51 | <0.01 |
NF-κB | 年龄、BMI、HOMA-IR | -0.30 | 0.01 |
IL-6 | 年龄、BMI、HOMA-IR | -0.40 | <0.01 |
TNF-α | 年龄、BMI、HOMA-IR | -0.37 | <0.01 |
IL-10 | 年龄、BMI、HOMA-IR | 0.27 | <0.01 |
HOMA-IR | 炎症因子、BMI | -0.36 | <0.01 |
FBG | 炎症因子、BMI | -0.32 | <0.01 |
HbA1c | 炎症因子、BMI | -0.33 | <0.05 |
[1] |
|
[2] |
|
[3] |
|
[4] |
林俏丽,李际强,白晓辉,等.阻塞性睡眠呼吸暂停低通气综合征患者外周血自噬相关分子和趋化因子的表达及临床意义[J].西部医学,2022,34(1):79-83.
|
[5] |
|
[6] |
|
[7] |
阻塞性睡眠呼吸暂停低通气综合征诊治指南(2011年修订版) //第四届东北地区呼吸疾病学术会议暨吉林省第十一届呼吸病学年会论文集[C]. 2012:67-70.
|
[8] |
|
[9] |
|
[10] |
|
[11] |
|
[12] |
|
[13] |
|
[14] |
|
[15] |
|
[16] |
|
[17] |
|
[18] |
|
[19] |
李燕,薛灏,陈丝丝,等. IL-41/Metrnl的生物学特性及在代谢与炎症相关疾病中的作用[J]. 生物化学与生物物理进展,2020,47(12):1285-1293. DOI:10.16476/j.pibb.2020.0145.
|
[20] |
|
[21] |
|
[1] | LIU Xinyi, LIU Zhandong. Research Progress of Anxiety and Depression Related to Chronic Fatigue Syndrome [J]. Chinese General Practice, 2023, 26(35): 4477-4482. |
[2] | LUO Weigang, YIN Yuanyuan, LIU Wanhu, XU Yuzhu, CAO Xiaoyun, BU Wei, ZHANG Lingyan, REN Huiling. Correlation of Triglyceride Glucose Index with Early Neurological Deterioration in Patients with Single Subcortical Infarction [J]. Chinese General Practice, 2023, 26(35): 4419-4424. |
[3] | LI Yuan, MU Yanling, XUE Mengzhou. Mechanism of Artesunate Regulating NLRP3/ASC/Caspase-1 Signaling Pathway to Reduce Inflammation and Protect Neurological Function in Mice with Intracerebral Hemorrhage [J]. Chinese General Practice, 2023, 26(33): 4194-4202. |
[4] | LIANG Xuemei, WANG Rui, ZHAO Yuhuan, XU Tianjiao, WANG Wei, SUN Weidong. Transcranial Low-level Laser Therapy: a Novel Treatment for Depression [J]. Chinese General Practice, 2023, 26(27): 3335-3341. |
[5] | KONG Dexian, XING Yuling, SUN Wenwen, ZHANG Zhimin, ZHOU Fei, MA Huijuan. Correlation between Estimated Glucose Disposal Rate and Metabolism-associated Fatty Liver Disease in Type 2 Diabetes [J]. Chinese General Practice, 2023, 26(26): 3252-3258. |
[6] | ZHU Li, XING Jiajia, WEI Juanfang, WANG Wenchun, ZHANG Anren. Research Advances in the Mechanism of Short-chain Fatty Acids in Neurodegenerative Diseases [J]. Chinese General Practice, 2023, 26(24): 3061-3066. |
[7] | GAO Zhe, DUAN Kaixin, LYU Xiuqin, MA Huijuan, ZHANG Zhimei, SONG Guangyao. Mechanism of Glucagon-like Peptide-1 Receptor Agonist Improving Liver Lipid Deposition in a Rat Model of Insulin Resistance Induced by High-fructose Diet [J]. Chinese General Practice, 2023, 26(21): 2639-2646. |
[8] | ZHOU Shiyu, CHEN Shaolin, DENG Renli, DAI Mi, LIU Tao, TIAN Kunming. The Association and Predictive Value of Lipid Ratios to Metabolic Syndrome: a Multistage Cross-sectional Study [J]. Chinese General Practice, 2023, 26(21): 2589-2596. |
[9] | ZHAO Lizhen, LI Weimin, JIANG Ruixia. Clinical Value of Systemic Immune-inflammation Index in the Diagnosis of Diabetic Kidney Disease in Community-dwelling Elderly Patients with Type 2 Diabetes [J]. Chinese General Practice, 2023, 26(18): 2227-2231. |
[10] | GOU Dengqun, ZHANG Lu, XU Yuanli, JIANG Mingjiao, WU Hemei, TAO Ming. Neutrophil-to-lymphocyte Ratio and Red Cell Distribution Width as Potential Biomarkers of Frailty: a Scoping Review [J]. Chinese General Practice, 2023, 26(17): 2169-2175. |
[11] | LUO Rong, WANG Yu, MIAO Afeng, WU Xiaoke. Influencing Factors of Insulin Resistance in Polycystic Ovary Syndrome Patients with Normal Body Mass Index [J]. Chinese General Practice, 2023, 26(17): 2102-2107. |
[12] | LI Xiaoxiao, BAI Yanjie, WANG Yan, ZHANG Yongchuang, CHEN Shuying, CHEN Limin. Advances of NLRP3 Inflammasome in Post-stroke Cognitive Impairment [J]. Chinese General Practice, 2023, 26(17): 2176-2182. |
[13] | SHEN Fei, JIANG Weiping, MEI Xiaobin, HAN Yiping, ZHAO Jiayi, FAN Jian, GU Juan, SHEN Yanhong, XU Hongmei, ZHANG Dan, MEN Ying, DING Haiguang, CHEN Caiping, HAN Junhua. Influence of Microbiota-modulating Agents on Gut Flora in Community Patients with Diabetic Nephropathy [J]. Chinese General Practice, 2023, 26(09): 1112-1117. |
[14] | TANG Zixuan, LI Jing, HUANG Qi, ZHANG Ying, ZHANG Han, WANG Qian, ZHANG Lin, CHENG Yao, LIAO Xin. Correlation between Adiponectin and Free Testosterone Index and Insulin Resistance in Patients with Polycystic Ovary Syndrome [J]. Chinese General Practice, 2023, 26(08): 927-932. |
[15] | LIU Taotao, LI Tianrong, WANG Xue, CHEN Jiameng, SHUAI Zhiqin, LI Lisheng, XU Shangfu. Nanoparticle- and Exosome-based Targeted Drug Delivery Systems Used in the Diagnosis and Treatment of Atherosclerosis: Opportunities and Challenges [J]. Chinese General Practice, 2023, 26(08): 903-910. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||